MosaiQ™ COVID-19 Antibody Microarray
Quotient response to COVID-19
MosaiQ COVID-19 Antibody Microarray
Learn more

Latest updates

Virus
News
Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody Test

JERSEY, Channel Islands, 28 September 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that on September 25, 2020, the U.S.

Quotient laboratory
News
Quotient Limited to Publish Quarterly Investor Presentation

JERSEY, Channel Islands, August 4, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020.

Quotient laboratory
News
Quotient Limited Reports First Quarter Fiscal 2021 Results and Business Update

•    Significant progress in three targeted areas of MosaiQ development – COVID-19 antibody test, potential new applications, and transfusion diagnostics 
•    Ten commercial placements of MosaiQ platform in Europe and the US

Quotient laboratory
News
Quotient Announces Equity Awards

JERSEY, Channel Islands, 23 July 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced that Dr. Isabelle Buckle, Ph.D. and Dr. Catherine Larue, Ph.D.

Quotient laboratory
News
Quotient Announces Appointment of Two New Board Members

JERSEY, Channel Islands, 23 July 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced changes in the composition of its board of directors that will take effect later this year.

Lab
News
Quotient Limited Reports Impressive Results from an Independent SARS-CoV-2 Antibody Detection Study Conducted in Spain

JERSEY, Channel Islands, July 20, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported that an independent study conducted in Madrid, Spain has confirmed the high perform

View all

Press releases

Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
Read More
Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody Test
Read More
Read all press releases

Events

02 Nov
Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
See all events
Who we are
The future made possible.
Building on over 30 years of experience in transfusion diagnostics, we deliver game changing diagnostic solutions, empowering our customers to realize their full potential and improve their business.
Learn more
Investors
10:15 AM EDT • Oct 22, 2020
QTNT
4.535USD
-0.98%
3 Months
6 Months
12 Months
Quotient Ltd
$
Careers
Careers
Help us achieve our mission to transform transfusion diagnostics and beyond.
Joining Quotient is an opportunity to become part of a team that will shape the future of transfusion diagnostics.
Learn more
Reagents
Alba by Quotient. Experience. Expertise. Value.
These are just some of the qualities that set us apart from the competition. You can have peace of mind using our products, which have been time-tested for more than 30 years.
Learn more

Latest social posts